Imaging Early Response of ER+, HER2- Breast Cancer to Aromatase Inhibitor (AI) Therapy May 5, 2022 By Jesse Bufkin
Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate-and High-Risk Meningiomas May 5, 2022 By Jesse Bufkin
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia May 5, 2022 By Jesse Bufkin
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy May 5, 2022 By Jesse Bufkin
Consent to Determine Eligibility for Adoptive T Cell Therapy Treatment Protocols May 5, 2022 By Jesse Bufkin
COPD Activity: SERT, Cytokines and Depression (The CASCADE Study) Protocol May 5, 2022 By Jesse Bufkin
Allogeneic Hematopoietic Cell Transplantation after Nonmeyeloablative Conditioning for Patients with Severe Systemic Sclerosis May 5, 2022 By Jesse Bufkin
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutatio May 5, 2022 By Jesse Bufkin
NOVEL LUNG TRIAL Extension and REVIVE PAS Study NORMOTHERMIC EX VIVO LUNG PERFUSION (EVLP) AS ASSESSMENT OF EXTENDED/MARGINAL DONOR LUNGS FOR TRANSPLANT May 5, 2022 By Jesse Bufkin
An open label, 52-week, safety and tolerability extension to a randomized, double-blind, placebo controlled study of LCQ908 in subjects with Familial Chylomicronemia Syndrome May 5, 2022 By Jesse Bufkin
